Peptides Similar to Melanotan-1

Peptides Related to Melanotan-1#

Several peptides share functional overlap with Melanotan-1 in tissue repair and healing research. Below is a detailed comparison of their mechanisms, efficacy, and potential for combination use.

Thymosin Beta-4 (TB-500)#

Objective: Compare the research efficacy of Melanotan-1 (afamelanotide) versus TB-500/Thymosin β4 and GHK-Cu, including head-to-head data where available.

Summary of findings

• Strength of evidence hierarchy • Afamelanotide: Multiple randomized/controlled clinical studies culminating in regulatory approvals for erythropoietic protoporphyria (EPP) in the EU (2014), US (2019), and Australia (2020). Trials demonstrate increased light exposure tolerance and improved quality of life; accepted dosing is a 16 mg implant about every 60 days. Safety is generally favorable (headache, fatigue, nausea, flushing). • Thymosin β4/TB-500: Phase 2 randomized, double-blind, dose‑escalation trials in dermal wound healing show accelerated healing vs placebo in venous stasis ulcers (median 39 vs 71 days) and a trend in pressure ulcers (22 vs 57 days), with early lesion-size improvements in epidermolysis bullosa (57% vs 30% at day 14; p=0.0149). Ophthalmic RGN‑259 (Tβ4) has randomized, placebo‑controlled, masked trials (ARISE‑1; n≈317) with corneal staining and symptom endpoints; phase 2 trials in dry eye and neurotrophic keratitis report sign/symptom benefits. No regulatory drug approvals identified in this corpus. Safety generally favorable. • GHK‑Cu: Human evidence largely cosmetic. Small randomized or split‑face controlled studies report reductions in wrinkle volume/depth and improvements in skin parameters; broader mechanistic/preclinical support is extensive. Clinical trials are small and cosmetic-level; no systemic regulatory approvals. Tolerability appears good for topical use.

• Head‑to‑head data • No head‑to‑head trials comparing afamelanotide to thymosin β4/TB‑500 or to GHK‑Cu were found. No multi‑arm trials including these peptides together were identified; comparisons must therefore be indirect across different indications and study designs.

Indication-focused comparison

• Phototoxic disorders (EPP) • Afamelanotide is the only peptide among the three with robust randomized/controlled evidence in EPP and with regulatory approval. It increases sunlight exposure and improves QoL. • Tβ4/TB‑500 and GHK‑Cu lack clinical programs in EPP in the retrieved evidence.

• Wound/skin ulcer healing • Tβ4/TB‑500 shows positive signals in Phase 2 RCTs: venous stasis ulcers (median time to healing 39 vs 71 days) and pressure ulcers (trend 22 vs 57 days); EB cohort shows early wound size reductions (57% vs 30%, p=0.0149). • GHK‑Cu: Human cosmetic studies indicate wrinkle and skin-structure improvements; some human data in topical wound contexts are reported in reviews, but rigorous large RCTs for chronic ulcers were not identified in this set. • Afamelanotide: Main efficacy is in phototoxic conditions; wound-healing evidence is not established in this corpus.

• Ocular surface disease • Tβ4 (RGN‑259) has randomized, placebo‑controlled, masked clinical trials in dry eye (ARISE‑1; n≈317) with defined sign/symptom endpoints; early studies in neurotrophic keratitis report healing benefits. • Afamelanotide and GHK‑Cu: No comparable ocular RCT programs found in the gathered evidence.

• Cosmetic anti‑aging/skin quality • GHK‑Cu: Small randomized/split‑face studies show reductions in wrinkle volume/depth and improvements in skin density/firmness; evidence base is primarily cosmetic and small-scale. • Afamelanotide and Tβ4/TB‑500: Not primary targets for cosmetic anti‑aging; limited or no randomized cosmetic trials in the retrieved evidence.

Safety and regulatory status

• Afamelanotide: Favorable safety and approved for EPP (EMA 2014, FDA 2019, TGA 2020); 16 mg implant every ~60 days is common practice.

• Tβ4/TB‑500: Generally well tolerated in Phase 1/2 trials; no regulatory drug approvals identified here.

• GHK‑Cu: Topical cosmetic safety generally good; no drug approvals identified.

• On research efficacy, afamelanotide stands out with high‑quality randomized/controlled evidence and regulatory approvals for EPP, demonstrating clinically meaningful benefits on light tolerance and quality of life.

• Thymosin β4/TB‑500 shows encouraging Phase 2 randomized evidence in wound/ulcer healing and controlled ophthalmic trials, with reported improvements in healing times and ocular signs/symptoms, but lacks completed Phase 3 approvals in this corpus.

• GHK‑Cu has human cosmetic randomized/split‑face data supporting wrinkle and skin-parameter improvements, but its evidence base is primarily small cosmetic studies and preclinical work; no therapeutic approvals.

• No head‑to‑head studies among these peptides were identified; comparisons are indirect across distinct indications and endpoints.

Embedded artifact with the comparative table follows.

KPV#

• Clinical evidence supports a complementary effect when afamelanotide (Melanotan-1; NDP-α-MSH) is combined with narrow-band UV-B (NB-UVB) phototherapy for vitiligo. A randomized multicenter trial (55 patients) reported significantly greater repigmentation with afamelanotide + NB-UVB vs NB-UVB alone (mean 48.64% vs 33.26%; P <.05), with earlier and stronger responses on the face and upper extremities (interpreted as complementarity with phototherapy). Reviews and cohort reports describe pilot and observational studies in which monthly afamelanotide implants with NB-UVB yielded higher responder rates, earlier onset of repigmentation, and median repigmentation around 66% in one observational series; hyperpigmentation was the most common adverse effect.
• Mechanistic complementarity for the afamelanotide + NB-UVB combination is biologically plausible: afamelanotide augments melanogenesis and may modulate local inflammation via MC1R, while NB-UVB promotes T-cell apoptosis, cytokine modulation (↓CXCL9/CXCL10, ↑IL-10), and melanocyte proliferation/migration, producing convergent pro-repigmenting effects.
• Registered clinical trials further corroborate active investigation of the combination: completed Phase 1/2 studies and an active Phase 3 trial of afamelanotide + NB-UVB in nonsegmental vitiligo (NCT01382589, NCT01430195, NCT04525157; NCT06109649).
• No empirical evidence was found for synergy/complementarity between afamelanotide and other healing peptides (e.g., KPV, KdPT, thymosin-β4/TB-500, GHK-Cu, BPC-157) in wound healing or tissue repair, either clinically or preclinically. A focused review of melanocortin peptides details benefits of NDP-α-MSH/analogues alone in animal wound and fibrosis models but does not report peptide–peptide combination studies with afamelanotide.

Limitations and gaps

• Evidence of synergy/complementarity with NB-UVB is based on improved outcomes vs phototherapy alone; formal synergy modeling was not reported. There is a notable absence of published peptide–peptide combination studies pairing afamelanotide with other “healing peptides.” Future controlled studies would be needed to test such combinations directly.

Key details and combination data are summarized below.

• Complementary effects: Afamelanotide + NB-UVB improves repigmentation magnitude and timing over NB-UVB alone in vitiligo, supported by a randomized trial and additional cohorts, with mechanistic plausibility for complementarity.
• Peptide–peptide combinations: As of the current evidence reviewed, no published preclinical or clinical studies demonstrate synergy or complementarity when combining afamelanotide with other healing peptides; reviews of melanocortin peptides emphasize single-agent benefits in wound healing models.

Mechanism Comparison#

Overlapping mechanisms with Melanotan-1.

• α-MSH: Shares the same receptor family (MC1R/MC3R/MC4R/MC5R) and canonical Gs→cAMP signaling; like afamelanotide, α-MSH can engage ERK/MAPK and PI3K/Akt branches depending on cell context.
• Melanotan II (MT-II): A cyclic, nonselective melanocortin agonist that activates MC1R and central MC3R/MC4R with potent Gs→cAMP signaling; it recruits similar downstream MAPK/PI3K pathways contextually. Thus, MT‑II overlaps with Melanotan‑1 at MC1R and shares broad melanocortin receptor engagement and cAMP-centric signaling.
• Bremelanotide (PT‑141): An MT‑II derivative with MC4R-predominant agonism that elevates cAMP in MC4R-expressing cells; it mechanistically overlaps with Melanotan‑1 through Gs→cAMP signaling at melanocortin receptors, albeit with a stronger central (MC4R) focus.
• Setmelanotide: A highly potent, MC4R‑selective agonist that robustly activates Gs→cAMP at MC4R; while it is more selective than Melanotan‑1, the shared melanocortin GPCR mechanism and overlapping non-canonical MC4R branches (ERK/PI3K, context-dependent) create mechanistic commonality.

Mechanistically distinct peptide.

• ACTH (1–24)/ACTH: Primarily acts at MC2R in an MRAP‑dependent manner to drive adrenal steroidogenesis via Gs→cAMP/PKA and additional ERK/p38 and Ca2+-linked signals. This receptor specificity and accessory protein requirement set ACTH apart from Melanotan‑1’s nonselective α‑MSH‑like profile with emphasis on MC1R.

In conclusion, Melanotan‑1 shares overlapping mechanisms with α‑MSH, Melanotan II, bremelanotide, and setmelanotide by engaging the melanocortin receptor family (especially MC1R and MC4R) and activating Gs→cAMP signaling with receptor- and context-dependent MAPK and PI3K/Akt branches. ACTH is mechanistically distinct due to its exclusive MC2R targeting and MRAP dependence for adrenal steroidogenic signaling.

Evidence Gaps#

Direct head-to-head comparison studies between Melanotan-1 and related peptides are limited. Most comparisons are based on separate studies with different methodologies, making direct efficacy comparisons difficult.

Related Reading#

• Melanotan-1 overview and research guide
• Melanotan-1 research evidence
• Melanotan-1 dosing protocols